Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-64 years old (both included) at screening.~* Diagnosis of atopic dermatitis (AD) (as defined by the American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year prior to screening.~* Subjects who have a recent history (within 6 months before screening) of inadequate response to treatment with topical medication, or for whom topical treatments are otherwise medically inadvisable.~* Eczema Area and Severity Index (EASI) score ≥12 at screening and ≥16 at baseline.~* Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) score ≥3 at screening and baseline.~* Body surface area (BSA) of AD involvement ≥10% at screening and baseline.~* Worst Daily Pruritus Numeric Rating Scale (NRS, weekly average) of ≥3 points at baseline.~Exclusion Criteria:~* Treatment with systemic immunosuppressive/immunomodulating medication, immunoglobulin/blood products, or phototherapy within 4 weeks or 5 half-lives prior to randomization, whichever is longer.~* Treatment with biologics within 5 half-lives (if known) or 16 weeks prior to randomization, whichever is longer.~* Treatment with topical corticosteroid(s) (TCS), topical calcineurin inhibitor(s) (TCI), topical phosphodiesterase-4 (PDE-4) inhibitor, or other topical prescription treatments within 1 week prior to randomization.~* Treatment with a live (attenuated) vaccine within 12 weeks prior to randomization.~* Clinically significant active chronic or acute infection requiring systemic treatment within 4 weeks prior to randomization that may compromise the safety of the subject.~* Skin infection within 1 week prior to the baseline visit.~* Presence of hepatitis B or C infection at screening.~* History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.~* Participant has a positive or indeterminate test for tuberculosis at screening.~* Participant is pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- LEO 138559 (Type: EXPERIMENTAL): Participants will receive injections of LEO 138559 from Week 0 (baseline) to Week 16 (end of treatment).
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive injections of placebo from Week 0 (baseline) to Week 16 (end of treatment).

Based on this trial design, predict the completion outcome and termination type (if applicable).